J&J in talks to acquire eye disease biotech for up to $3.4bnJohnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.Nov 15, 2026·2 sourcesWet AMDMergers & acquisitions (M&A)Macular edema treatmentMergers and acquisitionsFinancial tiesPharmaceutical IndustryBiotech innovationTexasDrug development00